SBNO2

Summary

SBNO2 (strawberry notch homolog 2, HGNC:29158) is a protein-coding gene on chromosome 19p13.3, encoding Protein strawberry notch homolog 2 (Q9Y2G9). Acts as a transcriptional coregulator, that can have both coactivator and corepressor functions.

Predicted to enable chromatin DNA binding activity and histone binding activity. Involved in several processes, including cellular response to interleukin-6; macrophage activation involved in immune response; and negative regulation of DNA-templated transcription. Predicted to be active in nucleus.

Source: NCBI Gene 22904 — RefSeq curated summary.

At a glance

• GWAS associations: 34
• Clinical variants (ClinVar): 351 total
• MANE Select transcript: NM_014963

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29158
Approved symbol	SBNO2
Name	strawberry notch homolog 2
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ00173, Stno, Sno
Ensembl gene	ENSG00000064932
Ensembl biotype	protein_coding
OMIM	615729
Entrez	22904

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 15 protein_coding, 4 retained_intron

ENST00000361757, ENST00000438103, ENST00000586109, ENST00000587024, ENST00000587655, ENST00000587673, ENST00000590176, ENST00000590446, ENST00000590998, ENST00000592222, ENST00000935175, ENST00000935176, ENST00000935177, ENST00000954690, ENST00000954691, ENST00000954692, ENST00000954693, ENST00000954694, ENST00000954695

RefSeq mRNA: 2 — MANE Select: NM_014963 NM_001100122, NM_014963

CCDS: CCDS45894, CCDS45895

Canonical transcript exons

ENST00000361757 — 32 exons

Exon	Start	End
ENSE00000655380	1109135	1109211
ENSE00000655389	1112189	1112301
ENSE00000655395	1114231	1114422
ENSE00000892424	1109292	1109423
ENSE00000892426	1109506	1109598
ENSE00000892431	1111506	1111614
ENSE00000892432	1111996	1112067
ENSE00000892434	1112402	1112537
ENSE00000892435	1112818	1112949
ENSE00000892436	1113535	1113704
ENSE00000892438	1116021	1116103
ENSE00001678578	1174172	1174268
ENSE00001692613	1147309	1147420
ENSE00001795081	1149369	1149442
ENSE00002286470	1154184	1154402
ENSE00002810471	1107638	1108704
ENSE00003477322	1108779	1108969
ENSE00003517168	1119011	1119164
ENSE00003518518	1123534	1123639
ENSE00003528424	1123942	1124022
ENSE00003549411	1122139	1122282
ENSE00003561948	1122894	1123045
ENSE00003585063	1111019	1111093
ENSE00003602448	1110745	1110888
ENSE00003615298	1116829	1116926
ENSE00003615603	1119906	1120023
ENSE00003631719	1122468	1122558
ENSE00003647800	1127604	1127765
ENSE00003656154	1122658	1122791
ENSE00003657251	1119516	1119621
ENSE00003657802	1109683	1109777
ENSE00003659824	1117323	1117499

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 97.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 49.3719 / max 919.1965, expressed in 1818 samples.

FANTOM5 promoters (19 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177990	28.1658	1810
177972	8.9296	1356
177989	3.1602	1515
177974	1.8177	767
177971	1.5627	600
177973	1.3239	600
177982	1.2986	483
177987	1.0130	388
177975	0.6473	403
177976	0.4936	291

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	97.82	gold quality
spleen	UBERON:0002106	95.53	gold quality
vermiform appendix	UBERON:0001154	95.41	gold quality
left uterine tube	UBERON:0001303	95.26	gold quality
upper lobe of left lung	UBERON:0008952	94.94	gold quality
granulocyte	CL:0000094	94.90	gold quality
omental fat pad	UBERON:0010414	94.49	gold quality
lower esophagus mucosa	UBERON:0035834	94.11	gold quality
esophagus mucosa	UBERON:0002469	94.07	gold quality
metanephros cortex	UBERON:0010533	93.93	gold quality
minor salivary gland	UBERON:0001830	93.91	gold quality
left adrenal gland cortex	UBERON:0035825	93.61	gold quality
saliva-secreting gland	UBERON:0001044	93.55	gold quality
sural nerve	UBERON:0015488	93.50	gold quality
skin of abdomen	UBERON:0001416	93.28	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.26	gold quality
left adrenal gland	UBERON:0001234	93.17	gold quality
adipose tissue	UBERON:0001013	93.15	gold quality
zone of skin	UBERON:0000014	93.07	gold quality
skin of leg	UBERON:0001511	93.07	gold quality
right lung	UBERON:0002167	92.92	gold quality
right lobe of thyroid gland	UBERON:0001119	92.51	gold quality
thoracic mammary gland	UBERON:0005200	92.48	gold quality
vagina	UBERON:0000996	92.47	gold quality
adenohypophysis	UBERON:0002196	92.36	gold quality
endocervix	UBERON:0000458	92.26	gold quality
ectocervix	UBERON:0012249	92.26	gold quality
subcutaneous adipose tissue	UBERON:0002190	92.22	gold quality
descending thoracic aorta	UBERON:0002345	92.12	gold quality
esophagus	UBERON:0001043	92.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.89

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MITF, STAT1, STAT3, TAL1

miRNA regulators (miRDB)

42 targeting SBNO2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-3663-3P	99.84	70.39	798
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-5582-5P	99.27	71.42	1879
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-661	99.09	65.94	2062

Literature-anchored findings (GeneRIF, showing 3)

• The SBNO2 is component of the pathways that contribute to the downstream anti-inflammatory effects of IL-10. (PMID:18025162)
• SBNO2 is a critical mediator of STAT3-driven hematological malignancies. (PMID:36630607)
• Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma. (PMID:36695974)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	sbno2b	ENSDARG00000016188
danio_rerio	sbno2a	ENSDARG00000098801
mus_musculus	Sbno2	ENSMUSG00000035673
rattus_norvegicus	Sbno2	ENSRNOG00000013987
drosophila_melanogaster	CG3491	FBGN0028887
drosophila_melanogaster	sno	FBGN0265630
caenorhabditis_elegans		WBGENE00002889

Paralogs (1): SBNO1 (ENSG00000139697)

Protein

Protein identifiers

Protein strawberry notch homolog 2 — Q9Y2G9 (reviewed: Q9Y2G9)

All UniProt accessions (4): Q9Y2G9, K7ENA9, K7ERL2, K7ES28

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a transcriptional coregulator, that can have both coactivator and corepressor functions. Inhibits the DCSTAMP-repressive activity of TAL1, hence enhancing the access of the transcription factor MITF to the DC-STAMP promoter in osteoclast. Plays a role in bone homeostasis; required as a positive regulator in TNFSF11//RANKL-mediated osteoclast fusion via a DCSTAMP-dependent pathway. May also be required in the regulation of osteoblast differentiation. Involved in the transcriptional corepression of NF-kappaB in macrophages. Plays a role as a regulator in the pro-inflammatory cascade.

Subunit / interactions. Interacts with TAL1; this interaction inhibits TAL1 occupancy of the DCSTAMP promoter, leading to the activation of the DCSTAMP promoter by the transcription factor MITF.

Tissue specificity. Detected in macrophages. IL10 regulates expression in a STAT3-dependent way.

Induction. Up-regulated by interleukin IL6 and soluble interleukin receptor IL6R in astrocytes.

Similarity. Belongs to the SBNO family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y2G9-1	1	yes
Q9Y2G9-3	2

RefSeq proteins (2): NP_001093592, NP_055778* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026741	SNO	Family
IPR026937	SBNO_Helicase_C_dom	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR039187	SNO_AAA	Domain
IPR057332	SBNO_a/b_dom	Domain

Pfam: PF13871, PF13872, PF25373

UniProt features (15 total): sequence conflict 5, region of interest 4, compositionally biased region 4, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2G9-F1	68.13	0.28

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 197 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_BONE_TRABECULA_MORPHOGENESIS, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, CROONQUIST_NRAS_SIGNALING_DN, GOBP_MACROPHAGE_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, MODULE_45, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, MODULE_16, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GTGCCTT_MIR506

GO Biological Process (16): macrophage activation involved in immune response (GO:0002281), bone mineralization (GO:0030282), osteoclast differentiation (GO:0030316), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of inflammatory response (GO:0050727), bone trabecula morphogenesis (GO:0061430), cellular response to lipopolysaccharide (GO:0071222), cellular response to interleukin-11 (GO:0071348), cellular response to interleukin-6 (GO:0071354), osteoclast fusion (GO:0072675), cellular response to leukemia inhibitory factor (GO:1990830), ossification (GO:0001503), regulation of DNA-templated transcription (GO:0006355), cell differentiation (GO:0030154), multinuclear osteoclast differentiation (GO:0072674)

GO Molecular Function (2): chromatin DNA binding (GO:0031490), histone binding (GO:0042393)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular response to cytokine stimulus	3
DNA-templated transcription	2
myeloid cell activation involved in immune response	1
leukocyte activation involved in immune response	1
immune response	1
macrophage activation	1
ossification	1
biomineral tissue development	1
myeloid leukocyte differentiation	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
inflammatory response	1
regulation of defense response	1
regulation of response to external stimulus	1
trabecula morphogenesis	1
response to lipopolysaccharide	1
cellular response to molecule of bacterial origin	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
response to interleukin-11	1
response to interleukin-6	1
syncytium formation by cell-cell fusion	1
multinuclear osteoclast differentiation	1
response to leukemia inhibitory factor	1
multicellular organismal process	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cellular developmental process	1
osteoclast differentiation	1
DNA binding	1
chromatin binding	1
protein binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1044 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SBNO2	VMP1	Q96GC9	543
SBNO2	ETV3	P41162	512
SBNO2	FAM174C	Q9BVV8	511
SBNO2	GAL3ST4	Q96RP7	504
SBNO2	ARHGAP45	Q92619	497
SBNO2	ARID5A	Q03989	455
SBNO2	C1GALT1C1	Q96EU7	448
SBNO2	POLR2E	P19388	426
SBNO2	FBXL4	Q9UKA2	425
SBNO2	MIDN	Q504T8	396
SBNO2	CBARP	Q8N350	396
SBNO2	EEF1A2	P54266	390
SBNO2	SBNO1	A3KN83	388
SBNO2	IL22RA2	Q969J5	378
SBNO2	TPGS1	Q6ZTW0	376

IntAct

6 interactions, top by confidence:

A	B	Type	Score
TCEAL1	CHEK1	psi-mi:“MI:0914”(association)	0.530
MYC		psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
SBNO2		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): SBNO2 (Affinity Capture-RNA), SBNO2 (Affinity Capture-RNA), SBNO2 (Proximity Label-MS), SBNO2 (Affinity Capture-MS), SBNO2 (Affinity Capture-RNA), SBNO2 (Affinity Capture-MS), SBNO2 (Affinity Capture-RNA), SBNO2 (Affinity Capture-MS), SBNO2 (Affinity Capture-MS), SBNO2 (Affinity Capture-MS), SBNO2 (Affinity Capture-MS), SBNO2 (Proximity Label-MS), SBNO2 (Proximity Label-MS), SBNO2 (Proximity Label-MS), SBNO2 (Proximity Label-MS)

ESM2 similar proteins: A0A0M5K865, A0A2H5RJD4, A0JND4, A4RKC3, A8N5E5, A8NS89, B0D0N9, B4IB36, B4QL99, B6K0N7, E9M7A1, F4IF36, F4JPP0, G4YRT1, G4YUT3, P06623, P09543, P0CV73, P93042, Q0E0Q3, Q0JLS6, Q0UI93, Q1LZE8, Q2H0G2, Q2M3Z7, Q2M3Z8, Q2M405, Q2M408, Q2QMH2, Q2R224, Q2VF19, Q43827, Q5M888, Q5RFD0, Q5RFL4, Q6FLD4, Q75EG6, Q7S8J7, Q803H0, Q810J8

Diamond homologs: A0JND4, A3KN83, A8JUV0, F4IF36, O01737, Q5BJL5, Q5F371, Q689Z5, Q7TNB8, Q9Y2G9, A1YVX4, A6H619, A8DZJ1, P41229, P41230, P47156, P58268, P58269, P58270, Q30DN6, Q38JA7, Q5F3R2, Q5XUN4, Q63625, Q6IQX0, Q80Y84, Q92782, Q92784, Q9BY66, Q9FNE9, Q9P1Y6, Q9QX66, Q9UGL1, Q9VMJ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

351 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	277
Likely benign	28
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

6130 predictions. Top by Δscore:

Variant	Effect	Δscore
19:1108702:TGC:T	acceptor_gain	1.0000
19:1108702:TGCC:T	acceptor_loss	1.0000
19:1108703:GCC:G	acceptor_loss	1.0000
19:1108705:C:CC	acceptor_gain	1.0000
19:1108776:CACC:C	donor_loss	1.0000
19:1108777:A:AC	donor_gain	1.0000
19:1108777:AC:A	donor_gain	1.0000
19:1108778:C:CC	donor_gain	1.0000
19:1108778:CC:C	donor_gain	1.0000
19:1108778:CCCA:C	donor_gain	1.0000
19:1108781:A:AC	donor_gain	1.0000
19:1108782:C:CC	donor_gain	1.0000
19:1108782:CTTG:C	donor_gain	1.0000
19:1108788:T:TA	donor_gain	1.0000
19:1108791:T:A	donor_gain	1.0000
19:1108796:T:A	donor_gain	1.0000
19:1108967:TTC:T	acceptor_gain	1.0000
19:1108967:TTCC:T	acceptor_loss	1.0000
19:1108968:TC:T	acceptor_gain	1.0000
19:1108968:TCCTG:T	acceptor_loss	1.0000
19:1108969:CC:C	acceptor_gain	1.0000
19:1108970:C:CC	acceptor_gain	1.0000
19:1108970:CTGCG:C	acceptor_loss	1.0000
19:1109287:CCTA:C	donor_loss	1.0000
19:1109288:CTA:C	donor_loss	1.0000
19:1109289:TA:T	donor_loss	1.0000
19:1109290:A:AC	donor_gain	1.0000
19:1109290:A:T	donor_loss	1.0000
19:1109290:AC:A	donor_gain	1.0000
19:1109291:C:CC	donor_gain	1.0000

AlphaMissense

8894 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:1110861:C:G	R971P	1.000
19:1112067:C:A	G877W	1.000
19:1112199:A:G	L873P	1.000
19:1112202:C:G	R872P	1.000
19:1112220:G:T	A866D	1.000
19:1112301:C:T	G839D	1.000
19:1112432:A:G	W829R	1.000
19:1112432:A:T	W829R	1.000
19:1112834:A:G	F788S	1.000
19:1112939:C:A	R753M	1.000
19:1112939:C:G	R753T	1.000
19:1119574:A:G	W439R	1.000
19:1119574:A:T	W439R	1.000
19:1119913:G:C	S420R	1.000
19:1119913:G:T	S420R	1.000
19:1119915:T:G	S420R	1.000
19:1119953:A:G	L407P	1.000
19:1122224:A:G	L355P	1.000
19:1122234:A:C	Y352D	1.000
19:1122538:A:G	L312P	1.000
19:1122552:G:C	S307R	1.000
19:1122552:G:T	S307R	1.000
19:1122554:T:G	S307R	1.000
19:1122659:A:G	W305R	1.000
19:1122659:A:T	W305R	1.000
19:1122724:C:T	G283D	1.000
19:1108779:C:G	G1206R	0.999
19:1108808:A:G	L1196P	0.999
19:1108872:A:G	W1175R	0.999
19:1108872:A:T	W1175R	0.999

dbSNP variants (sampled 300 via entrez): RS1000011064 (19:1150998 C>A,T), RS1000034376 (19:1163923 C>T), RS1000042851 (19:1108824 G>A), RS1000059511 (19:1168569 C>G), RS1000090208 (19:1168734 C>T), RS1000091974 (19:1113148 C>G), RS1000107114 (19:1113249 C>T), RS1000118111 (19:1152861 C>A,T), RS1000142269 (19:1154999 TCAGA>T), RS1000166107 (19:1123711 C>A,T), RS1000174738 (19:1113953 G>A,T), RS1000176275 (19:1125979 G>A,C), RS1000234615 (19:1152655 C>G), RS1000277147 (19:1154884 G>C,T), RS1000339305 (19:1127962 C>T)

Disease associations

OMIM: gene MIM:615729 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

34 associations (top):

Study	Trait	p-value
GCST000879_36	Crohn’s disease	8.000000e-12
GCST004131_43	Inflammatory bowel disease	5.000000e-17
GCST004132_20	Crohn’s disease	1.000000e-20
GCST004611_144	High light scatter reticulocyte count	5.000000e-21
GCST004612_91	High light scatter reticulocyte percentage of red cells	3.000000e-22
GCST004619_105	Reticulocyte fraction of red cells	3.000000e-17
GCST004622_70	Reticulocyte count	6.000000e-15
GCST004628_32	Immature fraction of reticulocytes	1.000000e-16
GCST005537_43	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	2.000000e-18
GCST005973_16	White blood cell count	1.000000e-08
GCST006288_370	Heel bone mineral density	2.000000e-06
GCST006288_670	Heel bone mineral density	5.000000e-18
GCST006288_71	Heel bone mineral density	2.000000e-11
GCST006979_737	Heel bone mineral density	2.000000e-65
GCST007400_43	Systemic lupus erythematosus	9.000000e-06
GCST007797_52	Asthma onset (childhood vs adult)	2.000000e-07
GCST007800_104	Asthma (childhood onset)	1.000000e-12
GCST007932_110	Medication use (thyroid preparations)	5.000000e-09
GCST007995_8	Asthma (childhood onset)	2.000000e-08
GCST012202_5	Distal/Left-sided colorectal cancer	2.000000e-08
GCST90002382_498	Eosinophil percentage of white cells	3.000000e-10
GCST90002385_302	High light scatter reticulocyte count	1.000000e-36
GCST90002386_51	High light scatter reticulocyte percentage of red cells	1.000000e-37
GCST90002387_222	Immature fraction of reticulocytes	5.000000e-35
GCST90002388_26	Lymphocyte count	3.000000e-14
GCST90002388_27	Lymphocyte count	2.000000e-14
GCST90002388_28	Lymphocyte count	8.000000e-13
GCST90002388_523	Lymphocyte count	3.000000e-32
GCST90002388_524	Lymphocyte count	1.000000e-11
GCST90002389_256	Lymphocyte percentage of white cells	2.000000e-12

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007986	reticulocyte count
EFO:0009270	heel bone mineral density
EFO:0004847	age at onset
EFO:0009933	Thyroid preparation use measurement
EFO:0007991	eosinophil percentage of leukocytes
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0010701	mean reticulocyte volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation	2
Nickel	increases expression	2
Ozone	affects expression, increases abundance, affects cotreatment, increases expression	2
aristolochic acid I	decreases expression, increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases methylation, affects cotreatment	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
propylparaben	increases expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
2,2’-methylenebis(4-methyl-6-tert-butylphenol)	affects expression, affects response to substance	1
beta-lapachone	increases expression	1
arsenite	affects binding, decreases reaction	1
methylparaben	increases expression	1
sodium arsenite	increases expression	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
bisphenol S	affects methylation	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Aripiprazole	increases expression, affects cotreatment	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects expression, affects methylation	1
Diazinon	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.